2141 Safety outcomes from 3 observational or phase 4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC). (September 2015) - Hurwitz, H.; Zafar, Y.; Kozloff, M.; Hubbard, J.; Van Cutsem, E.; Bennouna, J.; Arnold, D.; Bekaii-Saab, T.; Srock, S.; Revil, C.; Fish, S.; Barue, V.; et al.